The company continues to report zero meaningful revenue while sustaining a $4.2 million operating loss in 2026Q1, driven entirely by fixed R&D and administrative costs.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 208K | 43.49K | 589.46K | 611.69K | 143.17K | 59.77K | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | -100% | 378.29% | -92.62% | -3.63% | 327.26% | 139.51% | - | - | - | - |
| Cost of Goods Sold | 22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62.48K | 48 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 59.77K | -62.48K | -48 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | -100% | 195.66% | -131331.82% | - | - |
| Operating Expenses | 8.15M | 16.09M | 14.55M | 7.1M | 4.43M | 4.04M | 3.13M | -3.3M | -6.5M | -9.99M | -5.04M | -4.51M | -3.55M | 3.03M | 2.77M | 2.33M |
| OpEx % of Revenue | - | - | - | - | - | - | - | -1585.58% | -14935.41% | -1694.15% | -824.63% | -3151.69% | -5934.9% | - | - | - |
| Selling, General & Admin | 6.72M | 6.28M | 5.05M | 2.4M | 2.45M | 2.12M | 1.56M | 2.06M | 3.48M | 7.85M | 3.31M | 2.46M | 1.76M | 1.04M | 852.91K | 544.14K |
| SG&A % of Revenue | - | - | - | - | - | - | - | 992.31% | 8005.08% | 1331.77% | 540.6% | 1720.53% | 2942.53% | - | - | - |
| Research & Development | 10.07M | 9.81M | 9.5M | 4.7M | 1.97M | 1.81M | 1.53M | 1.61M | 3.03M | 3.21M | 2.88M | 2.27M | 1.85M | 1.99M | 1.92M | 1.79M |
| R&D % of Revenue | - | - | - | - | - | - | - | 772.12% | 6974.02% | 544.13% | 471.12% | 1584.4% | 3094.31% | - | - | - |
| Other Operating Expenses | -1.02M | 0 | 0 | 3K | 11K | 110K | 338K | -6.97M | -13.01M | -21.04M | -11.23M | -9.24M | -7.16M | 0 | 0 | 0 |
| Operating Income | -8.18M | -16.09M | -14.55M | -7.1M | -4.43M | -4.04M | -3.13M | 3.51M | 6.54M | 10.58M | 5.66M | 4.66M | 3.61M | 3.03M | 2.77M | -2.33M |
| Operating Margin % | - | - | - | - | - | - | - | 1685.58% | 15035.41% | 1794.15% | 924.63% | 3251.69% | 6034.9% | - | - | - |
| Operating Income Growth % | - | -10.61% | -104.77% | -60.29% | -9.7% | -28.99% | -189.33% | -46.38% | -38.17% | 86.99% | 21.49% | 29.05% | 19.14% | 9.17% | 218.86% | - |
| EBITDA | -8.12M | -16.05M | -14.51M | -7.09M | -4.41M | -4M | -3.08M | 3.56M | 6.6M | 10.64M | 5.72M | 4.7M | 3.64M | 3.06M | 2.8M | -2.31M |
| EBITDA Margin % | - | - | - | - | - | - | - | 1710.1% | 15170.6% | 1805.67% | 934.37% | 3283.05% | 6092.92% | - | - | - |
| EBITDA Growth % | 72.87% | -10.59% | -104.64% | -60.83% | -10.28% | -29.59% | -186.73% | -46.08% | -38.02% | 86.23% | 21.6% | 29.06% | 18.96% | 9.38% | 221.15% | - |
| D&A (Non-Cash Add-back) | 56K | 42K | 36K | 13K | 23K | 42K | 47K | 51K | 58.79K | 67.88K | 59.58K | 44.89K | 34.68K | 33.68K | 25.55K | 23.05K |
| EBIT | -17.03M | -19.39M | -21.97M | -7.1M | -4.43M | -3.98M | 0 | -3.51M | -6.7M | -10.3M | -5.39M | -5.83M | -3.61M | -3.03M | -2.76M | -2.33M |
| Net Interest Income | -96K | 0 | -566K | 7K | 8K | 26K | 98K | -10K | -17.36K | -27.43K | -15.59K | -12.68K | 2.75K | 0 | 1.29K | 0 |
| Interest Income | 29K | 0 | 62K | 7K | 11K | 26K | 98K | - | 0 | 0 | 629 | 2.52K | 0 | 0 | 7.9K | 0 |
| Interest Expense | 125K | 0 | 628K | 0 | 3K | 0 | 0 | 10K | 18.29K | 24.4K | 16.22K | 15.21K | 6.59M | 17.59K | 6.61K | 30.89K |
| Other Income/Expense | -8.71M | -3.3M | -8.05M | 7K | -3K | -27K | 338K | -7.02M | -13.25M | -20.9M | -11.07M | -10.5M | -626.93K | -6.77M | -2.77M | -30.89K |
| Pretax Income | -16.89M | -19.39M | -22.6M | -7.1M | -4.43M | -4.07M | -2.7M | -3.52M | -6.72M | -10.33M | -5.41M | -5.84M | 2.98M | -9.8M | 2.77M | 0 |
| Pretax Margin % | - | - | - | - | - | - | - | -1690.38% | -15442.01% | -1752.24% | -884.39% | -4080.67% | 4986.07% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.59K | 5.54M | 30.89K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.18% | 199.81% | - |
| Net Income | -16.89M | -19.39M | -22.6M | -7.1M | -4.43M | -4.07M | -2.7M | -3.52M | -6.72M | -10.33M | -5.41M | -5.84M | 2.98M | -9.8M | -2.77M | -2.36M |
| Net Margin % | - | - | - | - | - | - | - | -1690.38% | -15442.01% | -1752.24% | -884.39% | -4080.67% | 4986.07% | - | - | - |
| Net Income Growth % | 36.28% | 14.2% | -218.4% | -60.02% | -9.05% | -50.85% | 23.32% | 47.64% | 34.98% | -90.93% | 7.4% | -296.02% | 130.42% | -253.38% | -17.26% | - |
| Net Income (Continuing) | -16.89M | -19.39M | -22.6M | -7.1M | -4.43M | -4.07M | -2.7M | -3.52M | -6.72M | -10.33M | -5.41M | -5.84M | 2.98M | -9.8M | -2.77M | -2.36M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.31 | -21.56 | 60.76 | -38.30 | -28.66 | -26.32 | -17.88 | -29.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -126.75 | -6.78 | -6.04 |
| EPS Growth % | 93.46% | -135.48% | 258.64% | -33.64% | -8.89% | -47.2% | 39.39% | - | - | - | - | - | 100% | -1769.47% | -12.25% | - |
| EPS (Basic) | - | -21.56 | 60.76 | -38.30 | -28.66 | -26.32 | -17.88 | -29.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -126.48 | -6.78 | -6.04 |
| Diluted Shares Outstanding | 1.64M | 899.41K | 371.91K | 207.6K | 154.75K | 154.51K | 150.79K | 119.18K | 0 | 0 | 0 | 0 | 0 | 81.93K | 409 | 391.64K |
| Basic Shares Outstanding | 1.64M | 899.41K | 371.91K | 185K | 154K | 154K | 150K | 119K | 0 | 0 | 0 | 0 | 0 | 77K | 408 | 391.64K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | 12.43% | - | - | - |
Clinical trial funding shortfall
As reported in financial statements, GlucoTrack's cost structure remains entirely dominated by research and development expenditures, which reached $2.1 million in 2026Q1, reflecting the intensive engineering requirements of its multi-sensor fusion technology as the company attempts to transition toward a viable implantable continuous glucose monitoring system.
The absence of revenue means that every dollar spent on R&D directly exacerbates the company's net loss position. Investors should monitor whether the recent pivot to an implantable form factor will lead to a sustained increase in clinical trial costs, which could further strain the firm's limited liquidity.
Based on reported figures, the company's net income remains consistently negative, with a $4.3 million loss in 2026Q1, while stock-based compensation of $61,000 suggests that management is utilizing equity-based incentives to preserve cash in the absence of any meaningful commercial revenue generation or operational scale.
The volatility in EPS, which has fluctuated wildly between positive and negative values, appears to be a function of accounting adjustments rather than operational performance. This lack of earnings stability makes traditional valuation metrics unreliable and highlights the speculative nature of the current financial position.
According to recent SEC filings, GlucoTrack exhibits no operating leverage, as the firm has yet to generate revenue, resulting in an operating loss of $4.2 million in 2026Q1 that is entirely driven by the fixed costs of maintaining its R&D and administrative infrastructure.
Without a commercial product to scale, the company's operating expenses are essentially fixed, creating a high-risk environment where losses are decoupled from any potential revenue growth. Any future scaling will require a fundamental shift in the business model from development to commercialization, which remains unproven.
As indicated by the company's financial data, the reported cash balance of $7.38 million appears insufficient to support the current burn rate, suggesting that the firm may face significant dilution risks as it seeks to fund its ongoing clinical development and regulatory submission processes.
Short-term investors should be wary of the potential for further equity raises, which could significantly dilute existing shareholders. The reliance on external financing to sustain operations suggests that the company's survival is contingent upon market sentiment rather than internal cash generation.
Quick answers to the most common questions about buying GCTK stock.
For fiscal year 2025, GlucoTrack, Inc. (GCTK) reported total revenue of $0.0M.
GlucoTrack, Inc. (GCTK) reported a net loss of $19.4M for the fiscal year ending 2025.